Genus announce their half-year financial results and business highlights

The global cattle and pig breeding company Genus plc, which is headquartered in England, has just announced its half-year results, to 31 December 2014. There are several highlights:

· Revenue increased by 9% (up 13% in constant currency) with strong growth in Genus PIC (pig breeding), particularly in North America and growth in all Genus ABS (cattle breeding) geographies;

· Adjusted operating profit including joint ventures increased 15% (up 20% in constant currency) with Genus PIC profits up 14% (17% in constant currency) with strong contributions from North America, Mexico and Brazil. Genus ABS profits 3% were lower (up 2% in constant currency) with volume and revenue growth offset by higher product costs whilst Genus Asia profits 21% lower (down 18% in constant currency) primarily impacted by less activity in Russia, while China showed improvement;

· Adjusted earnings per share were up 21% (26% in constant currency);

· Strong net cash flow from operating activities of £19.6m (2013: £11.2m) and net debt of £73.2m (2013: £79.9m);

· Interim dividend is being increased 11% to 6.1 pence per share payable on 27 March 2014;
· Continued good progress in implementation of strategy:

1. Agreement was announced on 16 February 2015 to acquire 51% of In Vitro Brasil S.A. ('IVB'), the world leader in bovine in vitro fertilisation ('IVF'), for £4.6m adds important new capabilities to Genus ABS;

2. Birchwood Genetics Inc. were acquired in September 2014 to secure the long-term distribution of PIC proprietary boar genetics to mid-sized customers in North America;

3. The Génétiporc acquisition is now fully integrated following the exit from Quebec operations and consolidation of nucleus herds during the first half, a year ahead of original schedule, resulting in an acceleration of the delivery of synergy benefits from the transaction;

4.Genus’ Sexed Semen development project made good progress against plan and capital expenditure increased.

· Performance overall is ahead of expectations for 2015

Karim Bitar, Chief Executive, commented "Our strong performance in the first half demonstrated the success of our strategy and strength of our diverse geographic presence. Performance was particularly robust in PIC, where we were able to accelerate the delivery of synergies from the Génétiporc acquisition. We announced last week the acquisition of 51% of In Vitro Brasil, taking ABS into the rapidly developing area of bovine IVF, which enables customers to accelerate the genetic improvement of their herds. We are also pleased to have successfully completed the acquisition of Birchwood Genetics during the period, helping to build and sustain the success of the mid- and small-sized customers it serves. We are on course to perform above our original expectations for 2015, albeit we expect the pace of our growth to reduce in the second half of the year. Our confidence in the strategy for the business and in the future prospects for the Company is reflected in the 11% increase in our interim dividend." For more see


 24 February 2015